Importantly, co-immunostaining analysis confirmed that LLC tumor pericytes expressed HK2 (Supplementary fig. 8p), while the expression of pericyte-p-MLC2 was reduced in LLC/A549 tumors after treated with HK2 inhibitor as compared with placebo (Supplementary fig. 8q). The gene discussed is HK2; the disease is neoplasm.